In biofluid studies, cerebrospinal fluid ferritin predicts AD outcomes and associates with amyloid and tau measures, supporting disrupted iron homeostasis as an independent driver of disease progression (Du et al., 2024). This evidence concerns the gene MAPT and Alzheimer disease.